A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (NCT05514054)
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
🩺 Plain-English Summary (8th-Grade Level)
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.
Who can join: Review the eligibility criteria below.
Location: USO - Southern Cancer Center — Daphne, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (672 Sites)
Showing the first 25 of 672 sites.
- USO - Southern Cancer Center — Daphne, Alabama
- Clearview Cancer Institute — Huntsville, Alabama
- Infirmary Cancer Care — Mobile, Alabama
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- USO - Arizona Oncology Associates - HAL — Glendale, Arizona
- St. Joseph's Hospital and Medical Center — Phoenix, Arizona
- Mayo Clinic in Arizona - Phoenix — Phoenix, Arizona
- TMC HealthCare — Tucson, Arizona
- The University of Arizona Cancer Center - North Campus — Tucson, Arizona
- Highlands Oncology Group — Springdale, Arkansas
- UCSF - John Muir Health Cancer Center Berkeley — Berkeley, California
- Washington Health — Fremont, California
- Chao Family Comprehensive Cancer Center and Ambulatory Care (CIACC) - Irvine — Irvine, California
- Loma Linda University Cancer Center — Loma Linda, California
- Pacific Cancer Care — Monterey, California
- St. Joseph Hospital — Orange, California
- University of California, Irvine (UCI) Health - UC Irvine Medical Center — Orange, California
- University of California Davis (UC Davis) Comprehensive Cancer Center — Sacramento, California
- Kaiser Permanente San Diego Mission Road — San Diego, California
- Zuckerberg San Francisco General Hospital and Trauma Center — San Francisco, California
- UCSF Medical Center at Mission Bay — San Francisco, California
- Saint Joseph's Medical Center — Stockton, California
- Anschutz Cancer Pavilion — Aurora, Colorado
- UCHealth Memorial Hospital — Colorado Springs, Colorado
- UCHealth Harmony — Fort Collins, Colorado
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Neoplasms
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) — Birmingham, Alabama
- (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer — Phoenix, Arizona
- Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer — Dallas, Texas
- Assessment of Quality of Life and Treatment Times for Patients With Invasive Type Breast Cancer in Martinique — Fort-de-France,
- Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer — Springdale, Arkansas
- The IDEA Study (Individualized Decisions for Endocrine Therapy Alone) — Stanford, California
Explore by condition: All Breast Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.